NuVasive Gains Clearance for Expanded Use of Attrax Putty

NuVasive received FDA 510(k) clearance for expanded indications of use for Attrax® Putty with its thoracolumbar interbody portfolio for spine surgery. Attrax Putty is reportedly the first synthetic biologic to receive indications for use in interbody fusion of the thoracolumbar spine.

Attrax Putty is a synthetic, bioactive and osteoconductive...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us